METAVIA INC. (MTVA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
21/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinMTVA / S&P 19.17% / 15.20% |
LoseMTVA / S&P MTVA unavailable / 15.00% |
LoseMTVA / S&P -80.23% / 50.40% |
| 2026-Q10/3 |
LoseMTVA / S&P -85.75% / -4.33% |
LoseMTVA / S&P MTVA unavailable / 11.30% |
LoseMTVA / S&P -75.08% / 27.70% |
| 2025-Q40/3 |
LoseMTVA / S&P -18.57% / 2.65% |
LoseMTVA / S&P MTVA unavailable / 9.00% |
LoseMTVA / S&P -65.51% / 13.40% |
| 2025-Q32/3 |
WinMTVA / S&P 46.19% / 8.12% |
LoseMTVA / S&P MTVA unavailable / 4.61% |
WinMTVA / S&P 797.90% / 13.45% |
| 2025-Q21/3 |
LoseMTVA / S&P -58.25% / 10.94% |
LoseMTVA / S&P MTVA unavailable / 4.83% |
WinMTVA / S&P 770.02% / 10.63% |
| 2025-Q11/3 |
LoseMTVA / S&P -24.14% / -4.27% |
LoseMTVA / S&P MTVA unavailable / 4.98% |
WinMTVA / S&P 1191.13% / 10.57% |
| 2024-Q41/3 |
LoseMTVA / S&P -35.96% / 2.41% |
LoseMTVA / S&P MTVA unavailable / 5.25% |
WinMTVA / S&P 1510.16% / 6.15% |
| 2024-Q30/3 |
LoseMTVA / S&P -34.50% / 5.89% |
LoseMTVA / S&P MTVA unavailable / 5.89% |
LoseMTVA / S&P -86.13% / 6.11% |
| 2024-Q21/3 |
WinMTVA / S&P 18.34% / 4.28% |
LoseMTVA / S&P MTVA unavailable / 5.38% |
LoseMTVA / S&P -86.61% / 5.12% |
| 2024-Q11/3 |
WinMTVA / S&P 10.63% / 10.56% |
LoseMTVA / S&P MTVA unavailable / 5.71% |
LoseMTVA / S&P -91.97% / 5.59% |
| 2023-Q40/3 |
LoseMTVA / S&P -2.91% / 11.69% |
LoseMTVA / S&P MTVA unavailable / 6.81% |
LoseMTVA / S&P -94.34% / 7.78% |
| 2023-Q32/3 |
WinMTVA / S&P 8.92% / -3.27% |
LoseMTVA / S&P MTVA unavailable / 7.52% |
WinMTVA / S&P 119.12% / -5.03% |
| 2023-Q21/3 |
LoseMTVA / S&P -38.45% / 8.74% |
LoseMTVA / S&P MTVA unavailable / 9.50% |
WinMTVA / S&P 120.36% / -8.57% |
| 2023-Q11/3 |
LoseMTVA / S&P -1.11% / 7.50% |
LoseMTVA / S&P MTVA unavailable / 10.77% |
WinMTVA / S&P 205.79% / -15.69% |
| 2022-Q41/3 |
LoseMTVA / S&P -94.76% / 7.56% |
LoseMTVA / S&P MTVA unavailable / 11.88% |
WinMTVA / S&P 324.95% / -17.99% |
| 2022-Q31/3 |
LoseMTVA / S&P -4.93% / -4.88% |
LoseMTVA / S&P MTVA unavailable / 13.47% |
WinMTVA / S&P 153.47% / -1.41% |
| 2022-Q21/3 |
LoseMTVA / S&P -46.78% / -16.10% |
LoseMTVA / S&P MTVA unavailable / 13.71% |
WinMTVA / S&P 879.65% / 11.04% |
| 2022-Q10/3 |
LoseMTVA / S&P -26.07% / -4.60% |
LoseMTVA / S&P MTVA unavailable / 15.97% |
LoseMTVA / S&P MTVA unavailable / 42.23% |
| 2021-Q40/3 |
LoseMTVA / S&P -67.20% / 11.03% |
LoseMTVA / S&P MTVA unavailable / 15.00% |
LoseMTVA / S&P MTVA unavailable / 96.40% |
| 2021-Q31/3 |
WinMTVA / S&P 11.71% / 0.58% |
LoseMTVA / S&P MTVA unavailable / 10.77% |
LoseMTVA / S&P MTVA unavailable / 69.42% |
| 2021-Q20/3 |
LoseMTVA / S&P -24.32% / 8.55% |
LoseMTVA / S&P MTVA unavailable / 6.58% |
LoseMTVA / S&P MTVA unavailable / 51.81% |
| 2021-Q10/3 |
LoseMTVA / S&P -16.19% / 6.17% |
LoseMTVA / S&P MTVA unavailable / -1.06% |
LoseMTVA / S&P MTVA unavailable / 7.39% |
| 2020-Q40/3 |
LoseMTVA / S&P -6.58% / 12.15% |
LoseMTVA / S&P MTVA unavailable / -3.72% |
LoseMTVA / S&P MTVA unavailable / -33.42% |
| 2020-Q30/3 |
LoseMTVA / S&P -30.19% / 8.93% |
LoseMTVA / S&P MTVA unavailable / -2.04% |
LoseMTVA / S&P MTVA unavailable / -27.10% |
| 2020-Q20/3 |
LoseMTVA / S&P -42.09% / 20.54% |
LoseMTVA / S&P MTVA unavailable / -0.46% |
LoseMTVA / S&P MTVA unavailable / -27.11% |
| 2020-Q11/3 |
WinMTVA / S&P 58.86% / -19.60% |
LoseMTVA / S&P MTVA unavailable / 3.47% |
LoseMTVA / S&P MTVA unavailable / -14.75% |
| 2019-Q40/3 |
LoseMTVA / S&P -8.38% / 9.07% |
LoseMTVA / S&P MTVA unavailable / 5.36% |
LoseMTVA / S&P MTVA unavailable / 2.99% |
| 2019-Q30/3 |
LoseMTVA / S&P -52.84% / 1.70% |
LoseMTVA / S&P MTVA unavailable / 5.02% |
LoseMTVA / S&P MTVA unavailable / 0.21% |
| 2019-Q20/3 |
LoseMTVA / S&P -29.57% / 4.30% |
LoseMTVA / S&P MTVA unavailable / 6.64% |
LoseMTVA / S&P MTVA unavailable / 8.65% |
| 2019-Q11/3 |
WinMTVA / S&P 41.98% / 13.65% |
LoseMTVA / S&P MTVA unavailable / 8.12% |
LoseMTVA / S&P MTVA unavailable / 14.29% |
| 2018-Q40/3 |
LoseMTVA / S&P -60.68% / -13.52% |
LoseMTVA / S&P MTVA unavailable / 9.05% |
LoseMTVA / S&P MTVA unavailable / 18.23% |
| 2018-Q30/3 |
LoseMTVA / S&P -79.78% / 7.71% |
LoseMTVA / S&P MTVA unavailable / 10.21% |
LoseMTVA / S&P MTVA unavailable / 19.06% |
| 2018-Q21/3 |
WinMTVA / S&P 56.53% / 3.43% |
LoseMTVA / S&P MTVA unavailable / 9.03% |
LoseMTVA / S&P MTVA unavailable / 14.46% |
| 2018-Q10/3 |
LoseMTVA / S&P -18.06% / -0.76% |
LoseMTVA / S&P MTVA unavailable / 7.68% |
LoseMTVA / S&P MTVA unavailable / 12.46% |
| 2017-Q40/3 |
LoseMTVA / S&P -16.37% / 6.64% |
LoseMTVA / S&P MTVA unavailable / 7.03% |
LoseMTVA / S&P MTVA unavailable / 13.82% |
| 2017-Q30/3 |
LoseMTVA / S&P -25.78% / 4.48% |
LoseMTVA / S&P MTVA unavailable / 5.68% |
LoseMTVA / S&P MTVA unavailable / 17.57% |
| 2017-Q21/3 |
WinMTVA / S&P 21.90% / 3.09% |
LoseMTVA / S&P MTVA unavailable / 4.83% |
LoseMTVA / S&P MTVA unavailable / 17.74% |
| 2017-Q11/3 |
WinMTVA / S&P 33.93% / 6.07% |
LoseMTVA / S&P MTVA unavailable / 3.67% |
LoseMTVA / S&P MTVA unavailable / 13.32% |
| 2016-Q40/3 |
LoseMTVA / S&P -28.21% / 3.82% |
LoseMTVA / S&P MTVA unavailable / 2.09% |
LoseMTVA / S&P MTVA unavailable / 7.05% |
| 2016-Q30/3 |
LoseMTVA / S&P MTVA unavailable / 3.85% |
LoseMTVA / S&P MTVA unavailable / 0.20% |
LoseMTVA / S&P MTVA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | MTVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -76.20% | 20.78% |
| Annualized return | -76.20% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | MTVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.98% | 83.14% |
| Annualized return | -82.79% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | MTVA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -73.26% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |